Drug Overview
Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer.
Geodon initially launched in the US in 2001 for the treatment of schizophrenia.
It subsequently gained approval for bipolar disorder indications in the US and EU in August 2004 and October 2005, respectively.
In March 2011, Meiji Seika Kaisha acquired exclusive rights to develop and commercialize ziprasidone in Japan, with RaQualia Pharma being eligible for developmental milestones and royalties on commercial sales. RaQualia Pharma announced in March 2015 that it had initiated a Phase III trial in Japan studying Geodon for the treatment of schizophrenia. The author believes that the companies are focusing on development for schizophrenia first before pursuing bipolar disorder.
Geodon contains ziprasidone, a dopamine (D2) and serotonin (5-HT2) antagonist developed and marketed by Pfizer.
Geodon initially launched in the US in 2001 for the treatment of schizophrenia.
It subsequently gained approval for bipolar disorder indications in the US and EU in August 2004 and October 2005, respectively.
In March 2011, Meiji Seika Kaisha acquired exclusive rights to develop and commercialize ziprasidone in Japan, with RaQualia Pharma being eligible for developmental milestones and royalties on commercial sales. RaQualia Pharma announced in March 2015 that it had initiated a Phase III trial in Japan studying Geodon for the treatment of schizophrenia. The author believes that the companies are focusing on development for schizophrenia first before pursuing bipolar disorder.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES